Cellosaurus logo
expasy logo

Cellosaurus K562-r (CVCL_UC14)

[Text version]
Cell line name K562-r
Accession CVCL_UC14
Resource Identification Initiative To cite this cell line use: K562-r (RRID:CVCL_UC14)
Comments Population: Caucasian.
Doubling time: ~24-30 hours (ATCC=CRL-3344).
Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0004 (K-562)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-3344

Markers:
AmelogeninX
CSF1PO9,10
D5S81811,12
D7S8209,11
D13S3178
D16S53911,12
TH019.3
TPOX8,9
vWA16

Run an STR similarity search on this cell line
Publications

PubMed=10910924; DOI=10.1182/blood.V96.3.1070
Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., Vaz de Melo J.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 96:1070-1079(2000)

Cross-references
Cell line collections (Providers) ATCC; CRL-3344
Encyclopedic resources Wikidata; Q94335706
Entry history
Entry creation13-Nov-2018
Last entry update02-May-2024
Version number11